The Event: I called the mid-2026 STRO-004 readout a “make-or-break binary event.” This morning it arrived, alongside Q2 numbers. Dose escalation through 1–5 mg/kg (n=49), data cutoff July 24, 2026, and the core question — can Sutro hit Tissue Factor without the bleeding and ocular carnage that defines the class — got an encouraging first answer.
The Reaction: The stock closed at $21.30, down 36.6% from $33.59 on April 27. That drawdown happened before today’s print, in a market that had spent four months pricing in the possibility that the cell-free platform wouldn’t translate. What arrived was not a failure.
The Reality: This is a Phase 1 dose escalation in 49 heavily pretreated patients, unselected for target expression. It is not proof of efficacy. What it is is a clean read on the safety hypothesis that the entire thesis rests on — and the safety hypothesis held.
The Receipts
The tolerability numbers. Overall discontinuation due to adverse events was 6%. All-grade treatment-related AEs above 15% were nausea (33%), fatigue (29%), and anemia (18%). Grade 3+ events were essentially one thing: anemia at 14%, all grade 3. Dose-limiting toxicities appeared only at the top dose tested (5 mg/kg), drove dose reductions, and caused zero study drug discontinuations.
Why it matters: In my deep dive I wrote that Tivdak — the approved TF-ADC benchmark — carries black-box warnings and that up to 70% of treated patients experience treatment-emergent bleeding. STRO-004’s bleeding readout was epistaxis (nosebleeds) at 12%, predominantly grade 1–2. That is not a marginal improvement over the benchmark. That is a different safety category.
The ocular signal. Conjunctivitis 8%, dry eye 7%, predominantly grade 1–2. One grade 3 keratoconjunctivitis in 49 patients.
Why it matters: Ocular toxicity is the other half of the TF-ADC curse — the reason Tivdak patients need prophylactic eye drops and cooling eye pads. The preclinical package promised less corneal epithelial toxicity than the benchmark. In humans, so far, the eyes are mostly fine.
The PK — the part I find most persuasive. Half-life of nearly seven days, preserving 98% DAR8 configuration in circulation, with free exatecan concentrations described as low, delayed, and formation-limited. Dose-proportional exposure at every dose level, no evidence of target-mediated drug disposition. Management claims 25–50% more ADC exposure with at least 50% less circulating free payload versus conventional DAR8 exatecan ADCs.
Why it matters: Translate this. An ADC is a guided missile — antibody as guidance system, cytotoxin as warhead, linker as the pin holding them together. The failure mode for most ADCs is the pin slipping early, dumping warhead into the bloodstream where it poisons bone marrow and gut instead of tumor. “98% DAR8 preserved” means that after a week in circulation, essentially every antibody still carries its full complement of eight payloads. The stabilized β-glucuronidase linker I described as “a massive upgrade over standard protease-cleavable linkers” appears to be doing exactly what the chemistry said it would. Free payload staying below the neutropenia-risk threshold is why neutrophil count decreased shows up in only 6% of patients.
The efficacy signal — read carefully. Confirmed and ongoing unconfirmed partial responses across three tumor types in RECIST-evaluable patients: pancreatic, head and neck, and NSCLC, at the 3 and 4 mg/kg dose levels. Median of 3 prior lines of therapy, range 1–7. Eight tumor types, unselected for TF expression. In pancreatic and colorectal patients, 100% had prior irinotecan — a topoisomerase-1 inhibitor, meaning these are patients with pre-existing resistance to STRO-004’s payload class.
Q2 financials. Revenue $9.8M (vs. $63.7M in Q2 2025, which was inflated by the $53.2M Ipsen deferred-revenue derecognition). Net loss $38.5M, or $2.33/share. R&D plus G&A of $39.5M, down from $48.7M. Cash, equivalents and marketable securities of $164.3M, versus $202.6M at March 31 — runway reiterated into at least Q2 2028.
The timeline slip nobody is celebrating. Next STRIVE-01 update: first half of 2027. Expansion cohorts: also first half of 2027.
